PubRank

Francisco J López-Soriano

Author PubWeight™ 63.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009 1.52
2 Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003 1.20
3 Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 2003 1.18
4 The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 2005 1.16
5 Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 2004 1.16
6 Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004 1.15
7 Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care 2015 1.13
8 Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2004 1.12
9 Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev 2005 1.10
10 Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2011 1.09
11 Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett 2005 1.09
12 Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition 2005 1.03
13 Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal 2010 1.02
14 Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim Biophys Acta 2002 1.01
15 Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 2006 1.00
16 The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun 2002 0.98
17 Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012 0.98
18 Novel approaches to the treatment of cachexia. Drug Discov Today 2007 0.98
19 Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachexia Sarcopenia Muscle 2011 0.97
20 Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014 0.96
21 Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 2007 0.96
22 Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim Biophys Acta 2006 0.95
23 Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta 2006 0.94
24 The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett 2006 0.94
25 The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2011 0.94
26 Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. Obesity (Silver Spring) 2008 0.94
27 Myostatin: more than just a regulator of muscle mass. Drug Discov Today 2012 0.93
28 Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011 0.93
29 Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring) 2010 0.93
30 Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 2006 0.93
31 TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett 2002 0.92
32 Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta 2013 0.91
33 Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today 2008 0.90
34 Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol 2008 0.90
35 Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett 2005 0.90
36 The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 2005 0.89
37 Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle 2011 0.89
38 Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine 2003 0.89
39 Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 2008 0.88
40 Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep 2011 0.87
41 Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014 0.86
42 The pharmacological treatment of cachexia. Curr Drug Targets 2004 0.86
43 Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 2007 0.86
44 The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 2007 0.86
45 Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy? Clin Nutr 2007 0.85
46 L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr 2012 0.85
47 Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clin Nutr 2007 0.84
48 Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. J Lipid Res 2013 0.84
49 Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med 2005 0.84
50 Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol 2005 0.82
51 UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Lett 2008 0.82
52 Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res 2007 0.82
53 Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states? J Cell Physiol 2002 0.82
54 PPARdelta mediates IL15 metabolic actions in myotubes: effects of hyperthermia. Int J Mol Med 2009 0.81
55 Catabolic mediators as targets for cancer cachexia. Drug Discov Today 2003 0.81
56 Interleukin-15 increases calcineurin expression in 3T3-L1 cells: possible involvement on in vivo adipocyte differentiation. Int J Mol Med 2009 0.81
57 Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Lett 2003 0.81
58 Rat liver lipogenesis is modulated by interleukin-15. Int J Mol Med 2004 0.80
59 BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. Oncol Rep 2006 0.80
60 Sepsis induces DNA fragmentation in rat skeletal muscle. Eur Cytokine Netw 2004 0.80
61 Interleukin-15 affects differentiation and apoptosis in adipocytes: implications in obesity. Lipids 2011 0.80
62 [Physiology of sarcopenia. Similarities and differences with neoplasic cachexia (muscle impairments in cancer and ageing)]. Nutr Hosp 2006 0.79
63 Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma. Int J Mol Med 2004 0.78
64 Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle Nerve 2011 0.78
65 Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutr Metab (Lond) 2012 0.78
66 Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr 2010 0.78
67 Interleukin-15 decreases lipid intestinal absorption. Int J Mol Med 2005 0.77
68 The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways. FEBS Lett 2004 0.77
69 Targets in clinical oncology: the metabolic environment of the patient. Front Biosci 2007 0.77
70 Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia. FEBS Lett 2003 0.77
71 Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Exp Ther Med 2011 0.77
72 Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncol Lett 2011 0.77
73 Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: a role in muscle wasting? Biochim Biophys Acta 2005 0.76
74 Emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2007 0.75
75 Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting. Clin Nutr 2010 0.75
76 Plasma from pregnant rats has anti-tumoural activity. Oncol Rep 2004 0.75
77 Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncol Rep 2008 0.75
78 Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. Anticancer Res 2009 0.75
79 Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett 2002 0.75
80 A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation–contraction coupling together with additional muscle alterations. Muscle Nerve 2014 0.75